$6.48 -0.3 -3.9%
Last Trade - 4:00pm
Market Cap | £257.1m |
Enterprise Value | £216.2m |
Revenue | £n/a |
Position in Universe | 3941st / 6851 |
Sept 2 (Reuters) - Biomx Inc PHGE.A : * BIOMX ENTERS COLLABORATION WITH BOEHRINGER INGELHEIM WITH THE GOAL OF DISCOVERING MICROBIOME-BASED BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE * BIOMX ENTERS COLLABORATION WITH BOEHRINGER INGELHEIM WITH GOAL OF DISCOVERING MICROBIOME-BASED BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE * BIOMX - TO GENERATE METAGENOMIC DATA OF GUT MICROBIOME SAMPLES OBTAINED FROM IBD PATIENTS WITH AIM OF IDENTIFYING BIOMARKERS USING XMARKER PLATFORM * BIOMX INC - CONTINUES TO ADVANCE WHOLLY-OWNED PHAGE THERAPY CANDIDATE BX002 FOR TREATMENT OF IBD WITH A PHASE 1A STUDY EXPECTED TO BEGIN IN Q3 OF 2020 * BIOMX INC - TERMS INCLUDE AN OPTION FOR BOEHRINGER INGELHEIM TO NEGOTIATE AN EXCLUSIVE RIGHT TO BIOMARKERS DISCOVERED UTILIZING XMARKER PLATFORM Source text for Eikon: ID:nBw7m9PZVa Further company coverage: PHGE.A ((Reuters.Briefs@thomsonreuters.com;))